Danaher Corporation $DHR Stock Bought by Detalus Advisors LLC

Detalus Advisors LLC grew its stake in Danaher Corporation (NYSE:DHR) by 975.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,708 shares of the conglomerate’s stock after acquiring an additional 11,526 shares during the quarter. Detalus Advisors LLC’s holdings in Danaher were worth $2,815,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of DHR. Marquette Asset Management LLC grew its holdings in Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 73 shares during the period. N.E.W. Advisory Services LLC bought a new stake in Danaher in the second quarter valued at approximately $25,000. Main Street Group LTD bought a new stake in Danaher in the first quarter valued at approximately $25,000. Field & Main Bank acquired a new stake in Danaher in the second quarter worth $29,000. Finally, Evolution Wealth Management Inc. raised its holdings in Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 104 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Trading Up 3.0%

NYSE DHR opened at $231.52 on Friday. The stock has a market capitalization of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. The stock’s 50 day moving average price is $213.55 and its two-hundred day moving average price is $195.74. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business’s revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.77 EPS. As a group, analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on DHR shares. Royal Bank Of Canada lifted their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. Barclays lifted their price target on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Stifel Nicolaus reduced their price target on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Finally, Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.